Introduction
============

Annual estimates of the number of human immunodeficiency virus (HIV) infections in the United States peaked in the mid-1980s, decreased through the early 1990s, and remained relatively stable through 2010 \[[@ref1],[@ref2]\]. Over time, with improved diagnosis and treatment, the number of people living with HIV has steadily increased and with that has come the potential for increased HIV transmission \[[@ref3]-[@ref5]\]. But knowledge of HIV infection is associated with decreased risk behavior, and the proportion of persons with HIV in the United States who know their status is at its highest ever \[[@ref3],[@ref4]\]. Similarly, antiretroviral treatment (ART) for HIV substantially reduces the risk of viral transmission, and decreases in incidence have been observed in populations with higher uptake of ART \[[@ref6]-[@ref9]\]. Yet, it is unclear whether HIV prevention programs and ART use have resulted in decreasing HIV incidence in recent years in the United States.

A primary goal of the National HIV/AIDS Strategy for the United States is to reduce HIV incidence \[[@ref10]\]. However, determining progress in reducing HIV incidence is challenging as direct measures are generally not available. Some recent reports suggest that HIV diagnoses decreased in the United States during the last decade \[[@ref11]-[@ref13]\]. However, HIV diagnoses trends are affected by testing rates, diagnoses delays, and incidence rates, and should therefore be interpreted in conjunction with data on HIV testing and available incidence estimates.

To assess recent progress toward reducing HIV infections in the United States overall and in selected population segments with available incidence estimation methods, we analyzed data reported to national surveillance programs at the Centers for Disease Control and Prevention (CDC). The data presented include case counts of HIV diagnoses as well as data from new and established models to estimate HIV incidence and testing data from behavioral surveys to aid interpretation of trends. In the United States, large disparities in HIV diagnoses exist among population segments; two-thirds of persons with HIV diagnosed each year are men who have sex with men (MSM), and blacks or African Americans are 8 times and Hispanics or Latinos 3 times as likely to be diagnosed with HIV as white Americans \[[@ref14]\]. Therefore, assessment of progress toward reaching the goal of reducing HIV incidence should include trends for the United States overall and for disproportionately affected population segments.

Methods
=======

HIV Diagnoses and Incidence Data Sources and Methods
----------------------------------------------------

Data from the National HIV Surveillance System reported to the CDC through December 2015 were used to determine trends in the annual number of HIV diagnoses in the United States \[[@ref15]\]. Data on HIV diagnoses were also used to estimate the annual number of infections (incidence) with 3 models ([Table 1](#table1){ref-type="table"}) using (1) additional information on a biomarker that classifies infections as recent (or not) in the stratified extrapolation approach \[[@ref1],[@ref2],[@ref16]-[@ref18]\]; (2) HIV diagnoses and the severity of disease (whether infection is classified as stage-3 AIDS, within the same calendar year as HIV diagnosis) in the back-calculation approach (Bayesian hierarchical model) to estimate HIV prevalence and the percentage of persons living with undiagnosed HIV \[[@ref4],[@ref19],[@ref20]\]; and (3) the first CD4 count after diagnosis in a newly developed approach to derive incidence, prevalence, and the percentage undiagnosed (CD4 model) \[[@ref21]-[@ref23]\]. The biomarker data required for the stratified extrapolation approach were collected by 18 states and 3 cities participating in the incidence surveillance component of the National HIV Surveillance System. Incidence was estimated for these combined areas and then extrapolated to the remaining areas of the United States \[[@ref2]\]. For the Bayesian hierarchical model, input data were adjusted for underreporting of HIV diagnoses in the early years of the US epidemic period before HIV reporting was implemented by all jurisdictions, whereas information on AIDS diagnoses was available for all years \[[@ref19]\]. For the CD4 model historical data were not required and data on diagnoses and CD4 test results were directly obtained from the surveillance data.

Data are presented for 2008 through 2013; starting in 2008, all states and the District of Columbia had implemented name-based HIV reporting and these cases were reported to the National HIV Surveillance System. Diagnoses and incidence estimates were adjusted for missing risk factor information and for determining whether reporting delays may affect the interpretation of trends, we conducted analyses unadjusted and adjusted for reporting delays \[[@ref14]\].

Data on HIV diagnoses and for derived incidence include persons aged 13 years and older at the time of diagnosis or infection, respectively. Trends in these indicators were assessed overall and by sex and race or ethnicity (blacks or African Americans, (hereafter referred to as blacks); Hispanics or Latinos; and whites), and for MSM. HIV surveillance data can be considered to represent a census of HIV diagnoses for the United States and therefore no confidence intervals (CIs) are presented. For estimates of HIV incidence, 95% CIs were calculated. To determine whether there was a significant increasing or decreasing trend in the annual numbers of diagnoses or incidence, the estimated annual percent change (EAPC) in diagnoses and incidence and associated 95% CIs were calculated, and a change in trend was considered statistically significant if *P*\<.05.

###### 

Methods for estimating HIV incidence.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \                                                         Stratified extrapolation approach \[[@ref1],[@ref16],[@ref17]\]   Bayesian hierarchical model \[[@ref19],[@ref20]\]                                                                                                                 CD4 model \[[@ref23]\]
  \                                                                                                                                                                                                                                                                                             
  Name of the model                                                                                                                                                                                                                                                                             
  --------------------------------------------------------- ----------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------
  Method                                                    Biomarker-based sample survey                                     Bayesian-based back-calculation                                                                                                                                   CD4 based back-calculation

  Data requirement                                          Data for single or multiple years, no limit on number of years    Data for entire epidemic period                                                                                                                                   Data for recent (8+) years

  All new diagnoses                                         All new diagnoses                                                 All new diagnoses                                                                                                                                                 

  Incidence assay result on recency of infection            AIDS classification within year of diagnosis                      First CD4 after diagnosis                                                                                                                                         

  Testing and treatment history                             \                                                                 \                                                                                                                                                                 

  Strengths                                                 Annual estimates                                                  Annual estimates                                                                                                                                                  Annual estimates

  More accurate for recent years                            \                                                                 Data for entire epidemic period not required                                                                                                                      

  Weaknesses                                                False recent rate of incidence assay used                         HIV data in earlier years incomplete as jurisdictions implemented HIV reporting over time; hence relies on accuracy of data adjustment for incomplete reporting   Relies on accuracy of CD4 depletion model

  Relies on accuracy of testing and treatment information                                                                                                                                                                                                                                       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HIV Testing Data Sources and Methods
------------------------------------

Data on HIV testing among the US population are available from the National Health Interview Survey (NHIS) and the Behavioral Risk Factor Surveillance System (BRFSS), and these were used to determine trends in testing (a change in trend was considered statistically significant if *P*\<.05). NHIS collects information on a broad range of health topics from a nationally representative sample of civilian, noninstitutionalized US households \[[@ref24]\]. The annual NHIS response rate for the Sample Adult Survey ranged from 62.6% in 2008 to 60.8% in 2010 \[[@ref24]\]. NHIS asks persons aged 18 years and above questions related to HIV testing (Have you ever been tested for HIV? In what month and year was your last test for HIV \[the virus that causes AIDS\]?). Differences observed in estimates of HIV testing based on NHIS 2010 and earlier and NHIS 2011 and later may be attributable to survey design changes and estimates for the percentage of persons ever tested are not comparable \[[@ref25],[@ref26]\]. Therefore, the most recent years included in this analysis were 2008-2010. Only records for respondents aged 18-64 years were included, the age group for which CDC's recommendations encourage HIV screening, and records had to have a "Yes" or "No" response to whether the respondent had ever been tested for HIV, excluding tests for blood donations.

BRFSS is a state-based, random-digit-dialed telephone (landline and mobile) survey of the civilian, noninstitutionalized adult US population that collects information on preventive health practices and risk behaviors. In 2011, BRFSS added mobile phone numbers to the sampling frame and implemented a new weighting methodology. Differences observed in estimates of HIV testing based on 2010 and earlier BRFSS and 2011 and later BRFSS may be attributable to these design changes and estimates of the percentage of persons ever tested during the 2 periods are not comparable \[[@ref26]\]. The median weighted survey response rates for all states were 49.7% in 2011, 45.2% in 2012, and 45.9% in 2013 \[[@ref27]-[@ref29]\]. Ever tested for HIV and tested in the last year were based on respondents who reported having ever tested for HIV and whether the most recent HIV test was within a year of their BRFSS interview date. Analyses were weighted to account for the complex survey design, nonresponse, and sociodemographic factors to provide estimates of HIV testing that are representative of the civilian, noninstitutionalized population in the United States.

Data from National HIV Behavioral Surveillance (NHBS) for 2008, 2011, and 2014 were used to determine trends in HIV testing among MSM, ever and within the past 12 months. NHBS monitors HIV-associated behaviors in 20 cities with high AIDS burden \[[@ref30]\]. A venue-based sampling method is used for the NHBS MSM cycles \[[@ref31]\]. First, venues frequented by MSM (eg, bars, dance clubs, gyms, restaurants, parks, street locations, and social organizations) and days and times when men frequented those venues are identified. Second, venues and corresponding day-time periods were selected randomly for recruitment events. Third, men at recruitment events were systematically approached to screen for eligibility (aged ≥18 years, lived in a participating city, and able to complete the interview in English or Spanish). An additional eligibility criterion was applied in 2011 and 2014, by which only men who reported ever having sex with another man were eligible. Consent for participation in the survey was obtained and trained interviewers used handheld computers to administer a standardized anonymous questionnaire. All analyses were conducted using SAS version 9.3 statistical software (SAS Institute Inc), except for the Bayesian hierarchical model, which used R version 3.2.2 statistical software (The R Foundation for Statistical Computing).

Results
=======

HIV Diagnoses, Incidence, and Testing Among the US Population
-------------------------------------------------------------

Annual diagnoses decreased from 48,309 in 2008 to 39,270 in 2013, an average rate of 4.0% per year, and diagnoses adjusted for reporting delays decreased 3.1% per year from 48,938 in 2008 to 41,625 in 2013 ([Table 2](#table2){ref-type="table"}). In 2013, depending on the model used, an estimated 34,400 (95% CI 27,700-39,000) to 36,300 (95% CI 34,000-38,500) persons were newly infected with HIV in the United States. The CD4 model estimated an annual decrease of 4.6% in new infections from 2008 to 2013. The Bayesian hierarchical model also estimated a decrease in infections (2.6% per year) whereas the stratified extrapolation approach estimated stable numbers of new infections. During these years, the number of persons who reported ever having received an HIV test or having had a test within the past 12 months remained stable ([Figure 1](#figure1){ref-type="fig"}).

![Percentage of persons reporting testing for HIV, United States, 2008-2014. HIV: human immunodeficiency virus; BRFSS: Behavioral Risk Factor Surveillance System; NHBS: National HIV Behavioral Surveillance; NHIS: National Health Interview Survey; MSM: men who have sex with men.](publichealth_v3i1e8_fig1){#figure1}

###### 

Number of diagnoses of HIV infection and HIV incidence, by selected characteristics, United States, 2008-2013.

  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Measure                         Year                                EAPC^a^   *P* value                                                       
  ------------------------------- ----------------------------------- --------- ----------- -------- -------- -------- -------- -------- ------ --------
  **Total**                       \                                   \         \           \        \        \        \        \               

  \                               Diagnoses of HIV infection          No.       48,309      45,688   43,637   41,793   40,872   39,270   −4.0   \<.001

  estimated No.^b^                48,938                              46,428    44,564      43,043   42,686   41,625   −3.1     \<.001          

  \                               Stratified extrapolation approach   No.       39,000      36,100   35,300   36,900   36,700   36,200   −0.7   .22

  95% CI                          33,600                              31,100    30,500      31,800   31,600   31,200   \        \               

  44,400                          41,000                              40,200    42,000      41,800   41,300   \        \                        

  \                               Bayesian hierarchical model         No.       39,700      37,100   36,200   35,600   35,200   34,400   −2.6   \<.001

  95% CI                          36,900                              34,700    33,500      33,300   31,300   27,700   \        \               

  42,200                          39,900                              39,100    37,600      38,000   39,000   \        \                        

  \                               CD4 model                           No.       46,000      43,900   41,600   40,000   38,300   36,300   −4.6   \<.001

  95% CI                          44,800                              42,600    40,100      38,300   36,400   34,000   \        \               

  47,200                          45,200                              43,100    41,700      40,300   38,500   \        \                        

  **Black or African American**   \                                   \         \           \        \        \        \        \               

  \                               Diagnoses of HIV infection          No.       22,702      21,325   20,214   19,108   18,348   17,517   −5.0   \<.001

  estimated No.^b^                23,013                              21,695    20,669      19,722   19,234   18,666   −4.1     \<.001          

  \                               Stratified extrapolation approach   No.       17,600      15,400   14,800   16,200   15,200   15,600   −1.5   .09

  95% CI                          15,000                              13,200    12,600      13,800   12,900   13,300   \        \               

  20,200                          17,600                              17,000    18,500      17,400   17,900   \        \                        

  \                               Bayesian hierarchical model         No.       18,700      16,700   15,900   16,100   16,100   15,900   −3.1   \<.001

  95% CI                          16,400                              14,700    14,200      14,200   14,000   11,500   \        \               

  21,300                          18,700                              17,200    17,800      19,800   21,400   \        \                        

  \                               CD4 model                           No.       21,600      20,700   19,300   18,300   17,000   16,100   −5.7   \<.001

  95% CI                          20,700                              19,700    18,200      17,100   15,700   14,500   \        \               

  22,400                          21,600                              20,300    19,500      18,300   17,600   \        \                        

  **Hispanic or Latino**          \                                   \         \           \        \        \        \        \               

  \                               Diagnoses of HIV infection          No.       9801        9466     9158     8998     8997     8788     −2.0   \<.001

  estimated No.^b^                9928                                9615      9351        9263     9389     9299     −1.2     \<.001          

  \                               Stratified extrapolation approach   No.       7900        7600     7600     8100     8000     8100     1.0    .40

  95% CI                          6600                                6300      6400        6800     6700     6800     \        \               

  9200                            8800                                8800      9300        9200     9500     \        \                        

  \                               Bayesian hierarchical model         No.       8100        8000     8100     8300     8200     8100     0.4    .22

  95% CI                          7200                                6500      7000        7100     6100     5300     \        \               

  8900                            8900                                9100      9800        10,200   10,500   \        \                        

  \                               CD4 model                           No.       9500        9200     8800     8700     8700     8600     −2.2   .05

  95% CI                          8900                                8600      8100        7800     7700     7400     \        \               

  10,000                          9900                                9500      9500        9700     9700     \        \                        

  **White**                       \                                   \         \           \        \        \        \        \               

  \                               Diagnoses of HIV infection          No.       13,109      12,327   11,768   11,262   11,142   10,708   −3.8   \<.001

  estimated No.^b^                13,264                              12,506    11,993      11,559   11,574   11,275   −3.1     \<.001          

  \                               Stratified extrapolation approach   No.       11,100      10,900   10,800   10,400   11,100   10,600   −0.6   .63

  95% CI                          9300                                9100      9100        8700     9400     8900     \        \               

  12,900                          12,600                              12,500    12,100      12,900   12,300   \        \                        

  \                               Bayesian hierarchical model         No.       11,100      10,200   10,000   10,000   10,100   9800     −2.1   \<.001

  95% CI                          10,000                              8300      9000        8500     7800     6500     \        \               

  12,300                          11,200                              10,900    12,000      12,300   12,600   \        \                        

  \                               CD4 model                           No.       12,400      11,500   11,100   10,700   10,400   9500     −4.7   \<.001

  95% CI                          11,900                              10,900    10,400      9900     9500     8400     \        \               

  13,000                          12,100                              11,800    11,400      11,300   10,500   \        \                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------

^a^EAPC: estimated annual percent change.

^b^Numbers are adjusted for reporting delays.

HIV Diagnoses, Incidence, and Testing Among Population Segments
---------------------------------------------------------------

Among blacks, the number of HIV diagnoses decreased 5.0% per year from 2008 to 2013 (4.1% for diagnoses adjusted for reporting delays; [Table 2](#table2){ref-type="table"}). Among Hispanics or Latinos and whites, diagnoses decreased 2.0% (adjusted, 1.2%) and 3.8% (adjusted, 3.1%) per year, respectively. The CD4 model indicated decreases in incidence among blacks, Hispanics or Latinos, and whites, whereas the Bayesian hierarchical model indicated decreases among blacks and whites and the stratified extrapolation approach indicated that HIV incidence remained stable among all race or ethnicity groups.

Among males, the number of diagnoses decreased 2.8% per year from 2008 (36,614 diagnoses) to 2013 (31,578 diagnoses; decrease in adjusted diagnoses, 2.0%; [Figure 2](#figure2){ref-type="fig"}). Trends in estimated new HIV infections among males were inconsistent between the models. Incidence decreased by 3.5% (95% CI −4.6% to −2.4%) per year based on the CD4 model (2008: 35,600 infections, 95% CI 34,500-36,600; 2013: 29,600 infections, 95% CI 27,500-31,700), and by 1.5% (95% CI −1.9% to −1.2%) based on the Bayesian hierarchical model (2008: 31,500 infections, 95% CI 28,200-33,900; 2013: 28,900 infections, 95% CI 22,100-33,400). Based on the stratified extrapolation approach, HIV incidence remained stable among males (EAPC 0.9%, 95% CI −0.5% to 2.2%) from 2008 (29,400 infections, 95% CI 25,300-33,500) to 2013 (29,800 infections, 95% CI 25,700-34,000). The number of HIV diagnoses and infections among females decreased by about 30% between 2008 and 2013 using any measure, with average annual decreases in incidence from 4.2% to 8.7%.

Among men with infection attributed to male-to-male sexual contact, who accounted for 81.3% of males with HIV diagnosed in 2013, the number of HIV diagnoses decreased by 1.0% per year from 2008 (27,119 diagnoses) to 2013 (25,670 diagnoses), with no significant decrease observed in the diagnoses adjusted for reporting delays ([Figure 3](#figure3){ref-type="fig"}). During that time, the percentage of MSM who reported testing for HIV within the past 12 months increased from 63.0% in 2008 to 71.1% in 2014 (*P*\<.001; [Figure 1](#figure1){ref-type="fig"}). More than 90% of MSM reported ever testing for HIV in recent years. The number of new infections among MSM increased by 2.5% per year (95% CI 1.0%-4.0%) based on the stratified extrapolation approach (2008: 22,600 infections, 95% CI 19,400-25,800; 2013: 24,700 infections, 95% CI 21,200-28,200), but the CD4 model (EAPC −1.8%, 95% CI −3.0% to −0.5%; 2008: 27,400, 95% CI 26,500-28,200; 2013: 24,600, 95% CI 22,700-26,500) and Bayesian hierarchical model (EAPC −2.5%, 95% CI −2.9% to −2.1%; 2008: 25,700 infections, 95% CI 24,000-27,700; 2013: 22,800 infections, 95% CI 19,000-26,800) both indicated a decrease in HIV incidence ([Figure 3](#figure3){ref-type="fig"}).

![Number of diagnoses of HIV infection and estimated HIV infections, by sex, United States, 2008-2013. HIV: human immunodeficiency virus; BHM: Bayesian hierarchical model; CD4: CD4 model; SEA: stratified extrapolation approach.](publichealth_v3i1e8_fig2){#figure2}

![Number of diagnoses of HIV infection and estimated HIV infections among MSM, United States, 2008-2013. HIV: human immunodeficiency virus; BHM: Bayesian hierarchical model; CD4: CD4 model; SEA: stratified extrapolation approach; MSM: men who have sex with men.](publichealth_v3i1e8_fig3){#figure3}

HIV Incidence Adjusted for Reporting Delay
------------------------------------------

When analyses were repeated with data adjusted for delays in reporting of HIV diagnoses to the National HIV Surveillance System, the findings varied across models and population segments. For all 3 models, incidence estimates based on data adjusted for reporting delays did not change the interpretation of trends for blacks, whites, and females (data not shown). The Bayesian hierarchical model indicated a small increase in incidence overall (EAPC 0.8%, 95% CI 0.5%-1.1%) and among Hispanics or Latinos (EAPC 3.9%, 95% CI 3.2%-4.5%). For men with infection attributed to male-to-male sexual contact, estimates based on data adjusted for reporting delays from the CD4 (EAPC −1.0%, 95% CI −2.2% to 0.3%) and the Bayesian hierarchical models (EAPC 0.66%, 95% CI 0.31%-1.01%) no longer indicated a decrease in incidence.

Discussion
==========

Principal Findings
------------------

The study findings are that diagnoses of HIV infection and incidence estimates from 2 models indicate a reduction in HIV incidence from 2008 through 2013 overall and in subpopulations, including women, men, and MSM. Compared with earlier estimates of the number of new infections in the United States \[[@ref1],[@ref2],[@ref17]\], HIV incidence decreased from about 50,000 infections in the 1990s through the mid-2000s to around 36,000 infections in 2013. For MSM, previously published estimates \[[@ref1],[@ref2]\] indicate an increase in incidence from about 20,000 infections in the early 1990s to about 30,000 infections in the mid-2000s, with relatively stable incidence thereafter and, based on our analyses, about 25,000 infections in 2013. Our results from the stratified extrapolation approach for 2008-2010 are lower than the previously reported incidence estimates for these years (47,500, 45,000, and 47,000, respectively) based on the same model \[[@ref2]\]. There is new evidence that the mean recency period (an estimate of the time between seroconversion and the time the biomarker reaches a value defined as distinguishing recent vs long-standing infection) of the BED assay is longer than previously estimated \[[@ref18]\]. Use of a shorter recency period in the past resulted in an overestimation of incidence and therefore, a revision to modeling with the stratified extrapolation approach was required. We revised the method using the newly estimated recency period of 198 days for the BED assay (compared with 162 days used in the past) \[[@ref18]\].

Our analyses indicated substantial reductions in HIV incidence in the United States, including among blacks and Hispanics or Latinos, who are disproportionately affected by HIV. The results also suggest modest reductions among MSM, a population with a considerably higher HIV prevalence than heterosexuals, indicating the need for greater reach of HIV prevention services to make substantial reductions in incidence. HIV testing appears to be increasing among MSM, potentially due to large-scale national efforts, with a high and increasing proportion ever tested for HIV and more MSM tested within the past 12 months. This may be reflected in previously reported increases in HIV diagnoses among young MSM who are most likely to have undiagnosed HIV, and the overall increase in awareness of HIV infection among MSM \[[@ref4],[@ref11]\]. Annual testing is recommended for sexually active MSM and more frequent testing may be indicated for those at highest risk for HIV infection to detect HIV infection early, which allows risk counseling and initiation of treatment and is cost effective \[[@ref32]-[@ref34]\]. Additional assessments are needed to determine whether testing is not reaching certain subpopulations of MSM at high risk for HIV infection.

More work needs to be done to alleviate the possible reasons that HIV transmission continues at high rates among MSM, including a proportion of MSM with viral suppression well short of national goals \[[@ref4],[@ref10]\], increases in risk behavior \[[@ref35]\], and lack of substantial uptake of pre-exposure prophylaxis (PrEP) to date \[[@ref36]\]. The overall high proportion of undiagnosed HIV (51% in 2013) among young persons may contribute to higher HIV transmission \[[@ref4]\]. In addition, the proportion with a suppressed viral load is lower among younger compared with older MSM \[[@ref37]\]. With MSM accounting for the majority of transmissions of HIV in the United States \[[@ref14],[@ref38]\], it is crucial that prevention efforts reach all MSM.

Blacks and Hispanics or Latinos remain disproportionately affected by HIV compared with whites. In 2013, about 44% of persons who were infected with HIV were black and about 24% Hispanic or Latino, compared with them comprising 12% and 17% of the US population, respectively. The decreasing trends in diagnoses and incidence among women are encouraging and, as previously reported, are mirrored by decreasing diagnoses among black, Hispanic or Latino, and white women \[[@ref39]\]. Data on HIV testing in the United States for women overall do not indicate that decreases in diagnoses among women would be due to decreases in testing \[[@ref40]\]. However, some data indicate that testing among young women, including black and white young women, has decreased from 2011 to 2013 \[[@ref41]\], whereas data for women at increased risk for HIV infection from NHBS indicate an increase in testing \[[@ref42],[@ref43]\]. To achieve the goal of the National HIV/AIDS Strategy of reducing disparities in HIV, there is a need to strengthen treatment for persons living with HIV to improve their health and prevent transmission, as well as primary prevention efforts \[[@ref10]\]. Lower percentages of blacks and Hispanics or Latinos living with HIV have their infection diagnosed or are promptly linked to care after diagnosis \[[@ref4]\]. Disparities by race or ethnicity also exist in receipt of treatment and viral suppression overall as well as among women and MSM \[[@ref4],[@ref37],[@ref39]\].

Limitations
-----------

There are some limitations to each of the measures available to estimate trends in HIV incidence. Diagnoses represent a census of events for the United States. However, trends in diagnoses depend on testing rates and are subject to diagnosis delays, with an estimated median delay between HIV infection and HIV diagnosis of 3.6 years (mean 5.6 years) for 2011 \[[@ref21]\]. Back-calculation models to estimate incidence rely on valid input data on diagnoses and the time from infection to late stage disease ([Table 1](#table1){ref-type="table"}). An advantage to the CD4 model is that historical data are not required. The Bayesian hierarchical model, on the other hand, requires input data for the entire epidemic period and hence additional uncertainty is introduced because of the need to estimate HIV cases for the early years when HIV testing was not available and when few jurisdictions had HIV reporting even after HIV testing became available. Another advantage of the CD4 model is that HIV surveillance requires the reporting of the first CD4 count after HIV diagnosis in all jurisdictions, and CD4 reporting completeness is expected to increase as laboratory reporting improves \[[@ref4]\]. Collection of biomarker data for the stratified extrapolation approach is limited to the 18 states and 3 cities participating in incidence surveillance, requiring extrapolation to the remaining areas of the United States \[[@ref2]\]. The stratified extrapolation approach is also subject to incidence assay and testing history inaccuracies \[[@ref44]\]. In addition, stratified extrapolation approach estimates rely on a correctly calculated mean recency period for the incidence assay used. We applied the updated mean recency period of 198 days for the BED assay (compared with 162 days used in the past) \[[@ref18]\], which resulted in lower incidence estimates compared with earlier estimates. These limitations may also explain why the incidence estimates from the stratified extrapolation approach were at times inconsistent with the other 2 methods. Back-calculation models have greater uncertainty in later years reflected in wider CIs, and hence more uncertainty in determining trends. Estimating incidence by age with back-calculation models is more complex as age at HIV infection must also be estimated but could be included in future work. Reporting of HIV diagnoses is subject to reporting delays and duplicate reporting of cases, which primarily affect the reporting of data for the most recent years. Therefore, adjustment for reporting delays may overestimate diagnoses when duplicate cases have not been removed from the data. Finally, long-term trend data on testing rates to compare with diagnosis trends are not available for the general population or the entire population of MSM. The NHBS System relies on venue-based, time-space sampling of MSM in 20 large urban areas and therefore may not be representative of the entire MSM population. Testing data are also subject to accuracy of recall and possibly response influenced by social desirability.

Conclusions
-----------

In summary, incidence models estimated that about 36,000 people were infected with HIV in the United States in 2013. From 2008 to 2013, HIV diagnoses decreased overall, among both sexes and all race or ethnicity groups, and similar to earlier estimates of HIV incidence \[[@ref45],[@ref46]\], the CD4 and Bayesian hierarchical models indicated decreases in incidence. The overall decrease in incidence reflects a substantial decrease among women, heterosexual men, and as previously reported, among persons who inject drugs \[[@ref1],[@ref2]\]. However, further progress is dependent on effectively reducing HIV incidence among MSM, among whom the majority of new infections occur. To do so, the nation will need to accelerate access to testing, antiretroviral therapy, and prevention advances, including PrEP, to reduce HIV infections by the targeted 25% of the National HIV/AIDS Strategy \[[@ref10],[@ref47],[@ref48]\].
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